Atricure (ATRC) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is ATRC's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain manage…

AtriCure, Inc. ( ATRC ) 2026 UBS Global Healthcare Conference November 9, 2026 11:00 AM EST Company Participants Angela Wirick - Chief Financial Officer Conference Call Participants Patrick Andrew Wood - UBS Investment B…

AtriCure is shifting from targeting AF patients to all open-heart surgery patients, aiming for broader adoption as a preventive standard of care. Upcoming catalysts include the STS quality metric rollout in 2027, BoxX-No…

AtriCure, Inc. (NASDAQ:ATRC) on Tuesday posted upbeat results for the third quarter.…

AtriCure, Inc. ( ATRC ) Q3 2026 Earnings Call November 3, 2026 4:30 PM EST Company Participants Michael H. Carrel - CEO, President & Director Angela Wirick - Chief Financial Officer Conference Call Participants Marissa B…

AtriCure NASDAQ: ATRC reported third-quarter 2026 revenue of $154.5 million, up 15% from a year earlier, as growth in its U.S. open ablation, appendage management and pain management businesses helped lift profitability.…

The headline numbers for AtriCure (ATRC) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-…

AtriCure (ATRC) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to a loss of $0.01 per share a year ago.…

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain managem…

During the third quarter of 2026, the Small Cap strategy slightly underperformed its benchmark, the Russell 2000 Index, in a period in which small cap stocks broadly declined. Top contributors include AtriCure and Red Vi…

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain manage…

AtriCure, Inc. (NASDAQ: ATRC - Get Free Report) shares reached a new 52-week high during trading on Wednesday. The company traded as high as $60.99 and last traded at $60.9210, with a volume of 76652 shares traded. The s…

Here is how AtriCure (ATRC) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.…

The transaction was valued at $201,000. The sale represented 2% of the insider's direct equity holdings prior to the transaction.…

Investors need to pay close attention to ATRC stock based on the movements in the options market lately.…

AtriCure (ATRC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.…

Here is how AtriCure (ATRC) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.…

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain manage…

AtriCure is building a broader surgical platform across appendage management, ablation, and postoperative pain care. They have AtriClip, EnCompass, and cryoSPHERE. These products give them a diversified revenue base. How…
Kept in their own lane. A press release is the company talking, not reporting.
No upcoming events in the feeds.

